Compare · ARGX vs HRMY

ARGX vs HRMY

Side-by-side comparison of argenx SE (ARGX) and Harmony Biosciences Holdings Inc. (HRMY): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both companies sit in the Health Care sector. ARGX focuses on Biotechnology: Biological Products (No Diagnostic Substances), while HRMY focuses on Biotechnology: Pharmaceutical Preparations.
  • ARGX is the larger of the two at $58.81B, about 30.3x HRMY ($1.94B).
  • ARGX has been more active in the news (6 items in the past 4 weeks vs 5 for HRMY).
  • Both have 25 recent analyst ratings on file.
MetricARGXHRMY
Company
argenx SE
Harmony Biosciences Holdings Inc.
Price
-
-
Market cap
$58.81B
$1.94B
1M return
+14.67%
-
1Y return
+3.10%
-
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NASDAQ
IPO
2017
2020
News (4w)
6
5
Recent ratings
25
25
ARGX

argenx SE

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.À.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

HRMY

Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Latest ARGX

Latest HRMY